Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2010-06-30
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Amongst the multiple new pathways recently studied two have emerged as potentially important targets for new agents in lymphoma. These include the ubiquitin proteasome pathway and the biochemical reactions that control histone acetylation. The first two agents in each class to have been studied in lymphomas are: bortezomib and vorinostat. Bortezomib has been granted FDA approval for the treatment of mantle cell lymphoma and has established activity in a variety of B-cell lymphomas including follicular, marginal zone and diffuse large B-cell lymphoma. Vorinostat or SAHA (suberoylanilide hydroxamic acid) has been FDA approved for the treatment of refractory cutaneous T-cell lymphomas and has also shown activity in other lymphomas.
Synergistic activity between vorinostat and bortezomib has been observed in different cell lines. The proposed study will be a phase II trial of the combination of vorinostat and bortezomib at the recommended dose-schedule in patients with recurrent and/or refractory lymphomas, indolent and aggressive, and B or T.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combination Vorinostat + Bortezomib
Six cycle combination therapy with vorinostat and bortezomib.
Vorinostat in combination with Bortezomib
Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vorinostat in combination with Bortezomib
Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received 2 or \> prior therapies, which may include hematopoietic cell transplant (HCT)
* Received treatment with a nucleoside analog, or an alkylating agent, an anthracycline and/or in the case of B cell lymphomas, rituximab
* Resistant disease to 2 regimens or resistant disease to at least 1 regimen after first relapse
* Bi-dimensionally measurable disease documented within 30 days prior to enrollment. Bidimensionally measurable disease is defined as:
* A lymph node or tumor mass that can be accurately measured in two dimensions by CT,MRI, medical photograph (skin or oral lesion), plain X-ray, PET scan or other conventional technique and a greatest diameter of 1 cm or \>; or palpable lesions with both diameters \> 2 cm (lesion measured in 2 largest perpendicular dimensions in millimeters)
* For the purposes of this protocol, disease should be located in an area of no prior radiation therapy or a clear progression in an area that was previously irradiated
* Adequate organ and marrow function obtained \< or = to 14 days prior to enrollment as defined by a(n):
* ANC \> or = to 1,000/microliter
* Platelet count \> or = to 100,000/microliter, or \> or = to 75,000/microliter if the bone marrow is involved
* Hemoglobin level \> or = to 9 g/dL
* Total bilirubin \< or = to 1.5 x institutional upper limit of normality (ULN).(If abnormal, direct bilirubin less than or equal to 1.5 x institutional ULN)
* ALT or AST \< or = to 2.5 x institutional ULN (\< or = to 5 x institutional ULN if liver involvement with lymphoma)
* Serum creatinine \< or = to 1.5 x institutional ULN
* Zubrod (ECOG) Performance Status of 0 or 1
* Age \> than or = to 18 years
* Life expectancy \> or = to 3 months as clinically determined by referring physician
* Female patient is either post menopausal, free from menses for \> 2 years, surgically sterilized or willing to use highly effective methods of contraception (i.e., a condom in conjunction with a diaphragm, or spermicidal jelly; or oral, injectable, or implanted birth control; or abstinence ) to prevent pregnancy throughout the study, starting with visit 1
* Female patients of childbearing potential must have a negative serum pregnancy test (beta-HCG) within 72 hours of enrollment and should not be nursing due to the potential for congenital abnormalities and of harm to nursing infants due to this treatment regimen
* Male patient agrees to use an adequate method of contraception (i.e., a condom if female partner uses a diaphragm, spermicidal jelly; or oral, injectable, or implanted birth control; or abstinence) for the duration of the study and for 12 weeks after the last dose
* Patient must be able to swallow capsules
* Signed and dated IRB/ethics committee-approved informed consent before any protocol specific screening procedures are performed
* Both men and women of all races and ethnic groups are eligible for this trial
Exclusion Criteria
* CNS metastases, as indicated by clinical symptoms,cerebral edema, requirement for corticosteroids and/or progressive growth (treated CNS metastases must be stable for greater than 2 weeks prior to enrollment)
* Active second malignancy that requires treatment or that would interfere with assessment of response
* Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer with \< 5 years of documented disease-free status
* Treatment with the following within the timeframe specified prior to enrollment:
* Chemotherapy, radiotherapy, immunotherapy (active (such as vaccines) or passive (such as monoclonal antibodies or immunotoxins)) or major surgery \< or = to 3 weeks;
* Nitrosourea, or mitomycin \< or = to 6 weeks
* Radioimmunotherapy (e.g. Bexxar or Zevalin) \< or = to 12 weeks
* Concurrent enzyme-inducing anticonvulsant agents or valproic acid in last 4 weeks
* Prior bortezomib or any other proteasome inhibitor
* Prior vorinostat or any other histone deacetylase inhibitor
* Concurrent systemic corticosteroids (\<10 mg/day of prednisone or equivalent for adrenal insufficiency or acute allergic reactions allowed)
* Uncontrolled current illness including, but not limited to:
* Clinically or laboratory determined active infection
* Clinically limiting congestive heart failure or ejection fraction (EF) \<45%
* Clinically unstable angina pectoris (or myocardial infarction within 6 months of Day 1)
* Clinically significant cardiac arrhythmia
* Limiting pulmonary hypertension
* Pre-existing neuropathy ≥ grade 2
* Patients with pleural effusions, ascites or peripheral edema grade 2 or \>
* HIV
* Active viral hepatitis
* Major surgery or significant traumatic injury within 21 days prior to enrollment (this does not apply to placement of a venous access device)
* Hypersensitivity to any of the components in vorinostat or bortezomib or agents containing boron or mannitol
* Significant psychiatric illness/social situations that would limit compliance with study medication and requirements of the study as determined by study MD
* Significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the subject's risk by participating in this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Methodist Hospital Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hector A Preti, M.D.
Role: PRINCIPAL_INVESTIGATOR
The Methodist Hospital Research Institute
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0908-0284
Identifier Type: OTHER
Identifier Source: secondary_id
Pro00002085
Identifier Type: -
Identifier Source: org_study_id